These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33800934)

  • 41. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
    de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
    Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advanced Therapy Medicinal Products and the Changing Role of Academia.
    Priesner C; Hildebrandt M
    Transfus Med Hemother; 2022 Jun; 49(3):158-162. PubMed ID: 35813600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
    Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
    Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?
    Diebold Y; García-Posadas L
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
    Rivetti di Val Cervo P; Alessi E; Lastella M; La Greca A; Trotta F
    BioDrugs; 2024 Nov; 38(6):831-844. PubMed ID: 39404995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives.
    Roslin W; Mansnérus J
    Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell-based medicinal products approved in the European Union: current evidence and perspectives.
    Bellino S; La Salvia A; Cometa MF; Botta R
    Front Pharmacol; 2023; 14():1200808. PubMed ID: 37583902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advanced Therapeutic Medicinal Products in Bone and Cartilage Defects.
    Diaz-Solano D; Sadri B; Peshkova M; Shpichka A; Smirnova O; Shams R; Timashev P; Vosough M
    Curr Rev Clin Exp Pharmacol; 2024; 19(4):355-369. PubMed ID: 38275042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ATMPs for Cancer Immunotherapy: A Regulatory Overview.
    Galli MC
    Methods Mol Biol; 2016; 1393():1-9. PubMed ID: 27033211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. State-of-the-art knowledge on the regulation of advanced therapy medicinal products.
    Kidpun P; Ruanglertboon W; Chalongsuk R
    Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.
    Pizevska M; Kaeda J; Fritsche E; Elazaly H; Reinke P; Amini L
    Front Med (Lausanne); 2022; 9():757647. PubMed ID: 35186986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advanced Therapy Medicinal Products: What's in a Name?
    Jiskoot W
    J Pharm Sci; 2020 Nov; 109(11):3282-3284. PubMed ID: 32871153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
    Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
    Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
    [No Abstract]   [Full Text] [Related]  

  • 57. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.
    Carvalho M; Sepodes B; Martins AP
    Front Med (Lausanne); 2017; 4():182. PubMed ID: 29124055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
    Gonçalves E
    Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The advanced therapy classification procedure. Overview of experience gained so far.
    Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.